免疫检查点抑制剂的抗肿瘤临床实践与展望

基于靶向免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的肿瘤免疫治疗在近10年取得了重要进展,程序性死亡因子-1(PD-1)/程序性死亡因子配体-1(PD-L1)抗体治疗则成为肿瘤治疗领域最具潜力的新型疗法.中国肿瘤学者与发达国家学者基本同步开展的肿瘤免疫疗法的临床实践,进一步验...

Immune checkpoint inhibitors in anti-cancer therapy:practice and perspective

The immune checkpoint inhibitors (ICIs) have made great progress in the past decade. Especially the PD-1 / PD-L1 antibodies have become the most potential therapy among various new cancer treatments. Based on the rapid R&D process of PD-1 / PD-L1 antibodies, the parallel clinical trials carried out both in China and the developed countries proved the efficiency of PD-1 / PD-L1 antibodies towards various kinds of cancers. However, the drawbacks of PD-1 / PD-L1 antibodies also expose with more accumulated clinical data, including the low overall response rates (ORRs), the complex acquired drug resistances (ADRs) and various immune-related adverse events (irAEs), of which are worthy of attention of the oncologists. This paper summarizes the key progress of ICIs in clinics recently, discusses the above challenges, and proposes the strategy for increasing benefits of the ICI therapy.